Results 201 to 210 of about 252,112 (307)

Hydralazine Use and Risk of Vasculitis.

JAMA Netw Open
Fremont D, Dhaliwal S, Canney M, Akbari A, Hundemer GL, Derebail VK, Sood MM, Massicotte-Azarniouch D.   +7 more
europepmc   +1 more source

Co-produced evidence-based recommendations for cascade screening and secondary prevention in the relatives of people diagnosed with non-syndromic thoracic aortic disease. [PDF]

Front Cardiovasc Med
Abbasciano RG, Dionne JC, Miksza J, Oczkowski S, Barwell J, Shannon N, Grant R, Clift P, Proietti R, Hope E, Ahearn U, Hewitt K, Ghosh L, Kaur R, Lewis M, Cotton A, Skinner L, Saadia H, McManus G, Qureshi N, Aujla H, Page S, Sayers R, Bown M, Maltby J, Krasopoulos G, Cameron D, Oo A, Elefteriades J, Owens G, Murphy GJ.   +30 more
europepmc   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach. [PDF]

Rev Assoc Med Bras (1992)
Mutlu E, İnanç M.
europepmc   +1 more source

Vascular Calcification: Mechanisms, Models, and Therapies

iNew Medicine, EarlyView.
ABSTRACT Vascular calcification represents an active multifactorial process that mirrors several key features of skeletal bone mineralization. Clinically, it is characterized by diminished arterial compliance and increased arterial wall stiffness, both of which serve as independent predictors of significant adverse cardiovascular events.
Wenya Zhu, Shu Yang, Ziyi Chen, Xiaoxiao Yang, Zhen Liang, Yuanli Chen   +5 more
wiley   +1 more source

A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes. [PDF]

NPJ Drug Discov
Zhong X, Wei Q, Tiwari A, Wang Q, Tan Y, Chen R, Yan Y, Cox NJ, Li B.   +8 more
europepmc   +1 more source

A Just Transition: Lessons Learned from the Environmental Justice Movement [PDF]

, 2012
Farrell, Caroline
core   +1 more source

N6‐Methyladenosine (m6A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential

iNew Medicine, EarlyView.
ABSTRACT Accumulating evidence highlights the critical role of epigenetic modifications, particularly N6‐methyladenosine (m6A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m6A is dynamically regulated by multicomponent m6A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m6A‐binding ...
Yingfen Chen, Ru Ya, Ziling Zhang, Siyue Dong, Seol Hee Park, Wonhyo Seo, Yong He   +6 more
wiley   +1 more source

Association between plasma ceramide levels and endothelial dysfunction in patients with acute coronary syndrome: A prospective observational study. [PDF]

Medicine (Baltimore)
Chen J, Cheng Y, Cai X, Wang M, Zhang Z, Wei S, Zhou S, Chen Y.   +7 more
europepmc   +1 more source

Subject benchmark statement: architecture 2010 [PDF]

, 2010

core